Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getinge AB's total equity for the quarter that ended in Jun. 2026 was kr30,997 Mil.
This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.
Getinge AB Total Equity Related Terms
Getinge AB Total Equity Historical Data
* Premium members only.
The historical data trend for Getinge AB's Total Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Getinge AB (CHIX:GETIBS) has a Total Equity of kr30,997 Mil as of Jun. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Getinge AB and its competitors.
Is Getinge AB's Total Equity too high?
Getinge AB's current Total Equity is kr30,997 Mil. Overall, Getinge AB has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getinge AB's Total Equity compare to ABT and SYK?
Getinge AB's Total Equity of kr30,997 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Getinge AB and its competitors. Getinge AB's current Total Equity is kr30,997 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getinge AB stock overvalued right now?
Based on GuruFocus' analysis, Getinge AB (CHIX:GETIBS) is currently considered Modestly Overvalued. The stock's GF Value™ is kr192.70, compared to a current price of kr231.00 — trading 19.9% above its estimated fair value. The current Total Equity is kr30,997 Mil. Getinge AB's overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Getinge AB (CHIX:GETIBS), the current Total Equity is kr30,997 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getinge AB (CHIX:GETIBS) Overvalued in 2026?
Based on GuruFocus' analysis, Getinge AB stock appears to be overvalued.
The current stock price of kr231.00 is trading 19.9% above its estimated GF Value™ of kr192.70.
GuruFocus considers Getinge AB to be Modestly Overvalued.
Key valuation signals for CHIX:GETIBS:
Total Equity: kr30,997 Mil
GF Value™: kr192.70 vs. price of kr231.00 (19.9% above fair value)
No single metric tells the full story. See the CHIX:GETIBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (52% of revenue), surgical workflows (35%), and life sciences (13%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales, Europe, Middle East, and Africa 35%, and Asia-Pacific the remaining 25%.
73GF Score
Get the complete analysis for CHIX:GETIBS
Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GETIBS has been successfully added to your 
